Noriyuki Kasahara, MD, PhD

Noriyuki Kasahara, MD, PhD, has served as a member of our board of directors since September 2022. Dr. Kasahara brings more than 30 years of experience and has authored more than 150 peer-reviewed articles in the fields of gene therapy and genetic engineering. He is currently Professor and Alvera L. Kan Endowed Chair of Neurological Surgery and Radiation Oncology at the University of California San Francisco (“UCSF”), and a principal investigator in the UCSF Brain Tumor Center. The goals of Dr. Kasahara’s research include optimizing the application of multiple and diverse viral vector delivery systems to achieve maximal therapeutic potential, as well as developing next-generation gene transfer technologies with greater therapeutic efficacy in vivo.

He pioneered the development of tumor-selective retroviral replicating vectors (RRV) for gene therapy of cancer, including first-in-human multi-center clinical trials. Dr. Kasahara serves as a member of the Scientific Committee on Cancer Gene and Cell Therapy for the American Society of Gene and Cell Therapy, is on the Board of Directors of the Japan Society of Gene and Cell Therapy and is a past president of the International Society for Cell and Gene Therapy of Cancer.